Skip to main content
Equibles
EVFM logo

EVFM · Evofem Biosciences, Inc. · Investor Relations

Track EVFM — free

Use EVFM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research EVFM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$57.50 At close · Aug 11
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has concluded that these circumstances and the uncertainties associated with the Company's ability to obtain additional equity or debt financing on terms that are favorable to the Company, or at all, and otherwise succeed in its future operations raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$1.06M
Shares
132.53M
Volume · Aug 11 58.6K Avg daily vol (3M) —

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-09-23 Evofem Biosciences Adds Additional Manufacturing Capacity for PHEXX® to Support Global Growth Strategy
2026-08-14 Evofem Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-23 Evofem Biosciences Celebrates Shipment of Its 500,000th Unit of PHEXX®, Representing Hormone-Free Protection from Unintended Pregnancy for 6 Million Acts of Sex
2026-05-18 Evofem Reports First Quarter 2026 Financial Results and Provides Business Update
2026-04-27 Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa
2026-03-11 Evofem Reports Fifth Consecutive Year of Net Sales Growth
2026-02-04 What Female GLP-1 Users Need to Know This Valentine's Day: Your Medication Could Make Your Oral Birth Control Fail
2026-01-23 Evofem CEO Saundra Pelletier Calls for a “Ground-Up Reset” of Women’s Health at Fierce JPM Week 2026
2026-01-21 Evofem Expands “Say Vagina” Campaign With Launch of Say Vagina Store
2025-11-21 Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE
2025-11-13 Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update
2025-10-20 Evofem Announces Voting Results from Special Meeting of Stockholders
2025-10-01 Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates

Past events

Date Event Type
2026-08-03 STIMULATE Conference Conference
2026-01-14 Fierce JPM 2026 Keynote Address: Rebuilding Women’s Health from the Ground Up Event
2026-01-13 Global Innovation in Women's Health Pitch Showcase 2026: Keynote Address Event
2025-11-26 Evofem Biosciences Annual Meeting of Stockholders Shareholder meeting
2025-10-20 Evofem Biosciences Special Meeting of Stockholders Shareholder meeting
2025-08-01 Say Vagina Month Event
2025-04-17 Evofem Presentation at Emerging Growth 81 Investor Conference Conference
2023-09-14 Evofem Biosciences 2023 Annual Meeting of Stockholders Shareholder meeting
2023-06-11 CEO Saundra Pelletier TEDx talk: PROTECTION: It's Time For Women To Have Better Choices Event

Source: https://investor.evofem.com/

Key facts CIK 1618835 CUSIP 30048L302 Visit website Investor relations